Omega Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 20.21 million compared to USD 30.83 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.64 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.27 USD | -3.40% | -5.42% | -24.58% |
Apr. 16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
Apr. 16 | Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.58% | 125M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023